Michela Matteoli obtained her PhD in from the University of Pisa in 1989. Afterwards, she was EMBO postdoctoral fellow at the Yale School of Medicine, Department of Cell Biology, and Visiting Scientist at the University of Virginia School of Medicine. She established her lab in Milano as Researcher of the Italian National Research Council. In 2002 she became Associate Professor and in 2011 Full Professor of Pharmacology at the Università di Milano. Presently, she is Professor of Pharmacology at Hunimed University and Chair of the Neuroscience Program at the Clinical and Research Hospital. From 2014 to 2018 and from 2019 she is Director of the CNR Institute of Neuroscience, a prestigious Italian scientific Institution formed by 5 research sections, located in Pisa, Milano, Padova, Cagliari and Parma.
M Matteoli is Member of EMBO and of Academia Europæa. She is in the International Scientific Advisory Board (SAB) of the Paris School of Neuroscience and past member of the Armenise Harvard Foundation. She participates to the Scientific Council of the Umberto Veronesi Foundation. She was awarded in 2013 with the Mid Career Mentoring Award by the journal Nature, in 2015 with the Athena Award for scientific merits, and in 2019 with the Feltrinelli Award for Physiology, Biochemistry and Pharmacology.
Her research focuses on the synapse and how the immune system affects its formation and function. She authored about 160 publications, her h-index is 57 (Scopus) and she is in the list of Top Italian Scientists. Among the most recent contributions, her work showing that lack of TREM2 from microglia impairs synaptic pruning and causes sociability defects (Filipello, Morini et al. Immunity 2018, Impact Factor 22.8) has been selected among the best 10 papers of Immunity in 2018. Her group has also demonstrated that phosphatidylserine is a tag for synapses to be eliminated by microglial TREM2 (Scott-Hewitt, Perrucci et al., EMBO J. 2020) and that inflammation affects proteins involved in synapse function (Tomasoni et al, eLife 2017; Corradini et al., Biol. Psy. 2018). These findings have opened a novel avenue of research, centered around the new concept of immune-synaptopathies.